Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.31 |
| ▸ | RYR1 | P21817 | 2/20 | 0.31 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502249 | 0.87 | AURKA (0.37) | MAPT | |
| SCHEMBL4490589 | 0.77 | MAPT (0.33) | PARP1PARP10KDM4ELMNAMAPT | |
| SCHEMBL4495920 | 0.72 | PARP1 (0.39) | PARP1 | |
| SCHEMBL4708357 | 0.72 | POLB (0.37) | — | |
| SCHEMBL4510164 | 0.70 | CYP1A2 (0.39) | PARP1PARP10PDPK1PARP11KDM4E | |
| SCHEMBL12087018 | 0.69 | HTR2A (0.42) | PARP1PARP10PDPK1PARP11F7 | |
| SCHEMBL4718488 | 0.68 | ACHE (0.50) | PARP1PARP10PDPK1PARP11MAPT | |
| SCHEMBL4493259 | 0.67 | HTR1A (0.44) | PARP1PARP10KDM4EF7F3 | |
| SCHEMBL19229255 | 0.66 | ALDH1A1 (0.43) | PARP1PARP10PDPK1PARP11F7 | |
| SCHEMBL28757981 | 0.64 | ALDH1A1 (0.42) | LMNAMAPTHTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495111-B2 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1893617-A1 | TRICYCLIC COMPOUNDS USEFUL AS SEROTONIN INHIBITORS AND 5-HT1A AGONISTS AND ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2006138549-A1 | TRICYCLIC COMPOUNDS USEFUL AS SEROTONIN INHIBITORS AND 5-HT1A AGONISTS AND ANTAGONISTS | WYETH (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | HTR1A, HTR7, HTR3A | PARP1 3440/4885PARP10 2908/4885PDPK1 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.